Osteosarcoma drug pipeline grows with 25+ companies developing 32+ therapies including Phase III ADC and CAR-T treatments

The osteosarcoma treatment pipeline features over 25 companies developing more than 32 drugs, highlighting strong R&D activity in this bone cancer field. Key drugs in late-stage trials include HS-20093, an antibody-drug conjugate targeting B7-H3, and innovative therapies like TGF-β1 inhibitors and CAR-T cell treatments. This development reflects ongoing efforts to address unmet medical needs in osteosarcoma, a primary malignant bone tumor often affecting adolescents. The report covers clinical stages, drug types, administration routes, and collaborations, indicating a dynamic and evolving therapeutic landscape.